NSE: MANKIND | BSE: 543904

Expensive Performer

Download real time

2646.00 -6.30 (-0.24%)

39.19% Gain from 52W Low

415.0K NSE+BSE Volume

NSE 21 Jul, 2025 3:51 PM (IST)

109,208

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

Board Meeting

The next board meeting for Mankind Pharma Ltd. is on 31 Jul 2025 for the purpose of Quarterly Results & Interim Dividend See details

Mankind Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for MANKIND, BSE:543904 Mankind Pharma Ltd.

Mankind Pharma Ltd.

25 Apr 2023

2646.00

-0.24%

MANKIND PHARMA LTD.

IPO Note: Mankind Pharma Ltd.

Ventura

IPO NOTE

Number of FII/FPI investors increased from 640 to 648 in Jun 2025 qtr.

Mankind Pharma Ltd.

24 Apr 2023

2646.00

-0.24%

MANKIND PHARMA

IPO Subscribe: Mankind Pharma Ltd.

Hem Securities

Mankind Pharma Ltd. is trading above all available SMAs

Mankind Pharma Ltd.

24 Apr 2023

2646.00

-0.24%

Calibrated approach in domestic branded formulations.

IPO Subscribe: Mankind Pharma Ltd.

ICICI Direct

Mankind is the fourth largest player in the domestic market with a presence across therapy areas like anti-infectives, cardiac, gastro, respiratory and also in consumer healthcare segments like condoms, acne preparations, emergency contraceptives, pregnancy tests among others.

Number of FII/FPI investors increased from 640 to 648 in Jun 2025 qtr.

Mankind Pharma Ltd.

24 Apr 2023

2646.00

-0.24%

IPO Note

IPO Subscribe: Mankind Pharma Ltd.

Canara Bank Securities

Mankind Pharma Ltd. (“Mankind”) is India’s 4th largest pharmaceutical company in terms of Domestic sales and 3 rd largest in terms of sales volume for MAT (Moving An nual Total) December 2022 engaged in diverse range of pharmaceutical formulation across acute and chronic therapeutic areas.

Mankind Pharma Ltd. has gained 15.61% in the last 1 Month

Mankind Pharma Ltd.

24 Apr 2023

2646.00

-0.24%

Mankind Pharma Limited

IPO Subscribe: Mankind Pharma Ltd.

Asit C Mehta Investment Interrmediates

Mankind benefits from the industry experience and business acumen of their individual Promoters and is driven by the 3 core values of quality, affordability and accessibility. Their professional and experienced management team has been critical in building their brands, growing their operations, and maintaining capital efficiency despite their emphasis on affordable product offerings.

Number of FII/FPI investors increased from 640 to 648 in Jun 2025 qtr.

Mankind Pharma Ltd.

24 Apr 2023

2646.00

-0.24%

Strong domestic market position through a diversified product portfolio

IPO Subscribe: Mankind Pharma Ltd.

Aditya Birla Money Limited

MPL focuses primarily on the domestic market (98% of sales) with market share increasing from 4.1% to 4.3% over FY20 - MAT Dec’22 with sales growing at 12% CAGR v/s IPM (Indian Pharmaceutical Market) growth of around 10% for the same period.

Mankind Pharma Ltd. has an average target of 2784.33 from 3 brokers.

Mankind Pharma Ltd.

24 Apr 2023

2646.00

-0.24%

Mankind Pharma Ltd. IPO Note

IPO Note: Mankind Pharma Ltd.

Ashika Research

Mankind Pharma Ltd. has an average target of 2784.33 from 3 brokers.

Mankind Pharma Ltd.

24 Apr 2023

2646.00

-0.24%

Mankind Pharma Ltd: IPO

IPO Subscribe: Mankind Pharma Ltd.

ICICI Direct

Number of FII/FPI investors increased from 640 to 648 in Jun 2025 qtr.

Mankind Pharma Ltd.

21 Apr 2023, 12:00AM

2646.00

-0.24%

Leading domestic pharma player with diverse product portfolio

IPO Subscribe: Mankind Pharma Ltd.

Geojit BNP Paribas

Mankind Pharma Ltd (MPL) is the fourth largest pharmaceutical company in India by domestic sales and third largest by sales volume. With 97% of its revenue from India, MPL sells pharmaceutical formulations and consumer healthcare goods, and operates 25 manufacturing sites and a specialised R&D centre with four divisions.